Welcome to our dedicated page for BIOMARIN PHARMACEUTICAL SEC filings (Ticker: BMRN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
BioMarin Pharmaceutical Inc. filings document the regulatory record of a Nasdaq-listed biotechnology company focused on rare genetic diseases. Recent 8-K reports disclose operating and financial results, material events, material agreements, capital-structure matters and clinical or regulatory updates tied to products and programs such as VOXZOGO, PALYNZIQ, GALAFOLD and POMBILITI + OPFOLDA.
The company’s proxy materials describe board composition, shareholder voting matters, executive compensation, equity awards and other governance disclosures. Filing records also cover common stock listing details, financing activities, acquisition-related disclosures and business updates affecting BioMarin’s commercial rare-disease portfolio and development pipeline.
BioMarin Pharmaceutical EVP and CFO Brian Mueller reported routine equity compensation and related tax withholding. He received a stock option grant for 44,600 shares of common stock at an exercise price of $57.43 per share, vesting partly from March 16, 2027 through monthly installments until 2031. He was also granted 18,740 shares of common stock as restricted stock units with no purchase price.
To cover tax obligations on a prior vesting event, 9,945 shares of common stock were withheld at $58.51 per share, a non‑market disposition. Following these transactions, Mueller directly holds 125,431 common shares and the new option for 44,600 shares.
BioMarin Pharmaceutical CEO Alexander Hardy reported new equity awards and a routine tax withholding. On March 16, 2026, he received a grant of 89,200 stock options to buy common stock at an exercise price of $57.43 per share, expiring on March 15, 2036. The option grant vests 12/48 on March 16, 2027 and 1/48 on the 16th day of each month thereafter. He was also granted 62,440 restricted stock units on the same date, with price not applicable. On March 13, 2026, 2,941 shares of common stock were withheld at $58.51 per share to cover tax obligations. Following these transactions, Hardy directly owned 218,887 shares of BioMarin common stock.
BioMarin Pharmaceutical Inc. is halting dosing and enrollment in its Phase 2 trials of VOXZOGO for Turner syndrome, SHOX-deficiency and Aggrecan (ACAN)-deficiency. This decision follows several slipped capital femoral epiphysis (SCFE) events reported in two ongoing investigator-sponsored trials using VOXZOGO in these conditions.
BioMarin states that SCFE has not been seen in its own Phase 2 trials in these indications, nor among more than 5,000 infants and children treated with VOXZOGO for achondroplasia over about 10,000 patient-years of clinical and post-marketing safety data. No SCFE cases have appeared in VOXZOGO trials for hypochondroplasia. The Phase 2 CANOPY trials of VOXZOGO will continue for children with Noonan syndrome and for most participants with idiopathic short stature without ACAN-deficiency.
BioMarin Pharmaceutical EVP and Chief Technical Officer Charles Greg Guyer sold common shares in an open-market transaction. On March 11, 2026, he sold 16,486 shares of BioMarin common stock at a weighted average price of $60.46 per share, with individual sale prices ranging from $60.39 to $60.62. After this sale, he directly held 79,953 shares of BioMarin common stock.
BMRN Form 144 filing reporting an intended sale of Common Stock through a broker. The filing lists Fidelity Brokerage Services LLC as the broker and shows 03/11/2026 as a filing date.
The filing itemizes securities tied to compensation and ESPP with quantities and dates: 1,857 shares (restricted stock vesting on 05/04/2023), 133 shares (ESPP purchase on 10/31/2023), and 14,496 shares (restricted stock vesting on 03/15/2024).
Guyer Charles Greg reported acquisition or exercise transactions in this Form 4 filing.
BioMarin Pharmaceutical executive Charles Greg Guyer, EVP and Chief Technical Officer, reported three equity awards credited on February 25, 2026. The awards represent performance-based restricted stock units earned for results over 2023–2025 tied to relative total shareholder return, development goals, and core operating margin, vesting on March 15, 2026 if he remains in service.
BIOMARIN PHARMACEUTICAL INC executive Gregory R. Friberg, EVP and Chief R&D Officer, reported an open-market sale of 6,326 shares of common stock on February 26, 2026. The shares were sold at a weighted average price of $60.3758 per share, with individual sale prices ranging from $60.36 to $60.51 according to the footnote. After this transaction, Friberg directly holds 37,578 shares of BioMarin common stock.
BioMarin Pharmaceutical EVP and Chief Legal Officer George Eric Davis reported both stock sales and equity awards. On February 26, 2026, he completed an open-market sale of 26,061 shares of common stock at $61.36 per share, leaving 72,453 shares held directly afterward.
On February 25, 2026, he acquired three blocks of common stock through grants or awards totaling 15,224 earned restricted stock units (RSUs), all at a stated price of $0.00 per share. These RSUs were earned under performance-based awards tied to relative total shareholder return, development goals, and core operating margin for 2023–2025, and will vest on March 15, 2026 subject to continued service and certain earlier-vesting events.
BioMarin Pharmaceutical executive Brian Mueller received multiple performance-based stock awards. On February 25, 2026, he acquired 6,683, 7,230, and 2,569 shares of common stock at $0 per share through grants classified as awards, not open-market purchases.
These shares come from Restricted Stock Units earned for performance over 2023–2025, based on relative total shareholder return, development goals, and core operating margin. The earned RSUs convert into common stock on a 1:1 basis and are scheduled to vest on March 15, 2026, subject to his continued service, with earlier vesting possible upon certain events. Following these awards, he directly owns 116,638 common shares.
BioMarin Pharmaceutical Inc. notice of proposed sale of common stock on a Form 144 through a broker-dealer. The filing lists Fidelity Brokerage Services LLC and references proposed transactions tied to restricted stock vesting on 09/30/2025 (5928 shares) and an ESPP purchase on 10/31/2025 (398 shares). The form records the broker and an entry date of 02/26/2026.